Prevention of chemotherapy-induced neutropenia with pegfilgrastim: Pharmacokinetics and patient outcomes

Chemotherapy

Volumn 58, Issue 5, 2013, Pages 387-398

  Yang, Bing Bing ^a   Savin, Michael A ^b   Green, Michael ^c  

^a AMGEN INC   (United States)

^b TEXAS ONCOLOGY   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Chemotherapy induced neutropenia; Granulocyte colony stimulating factor; Pegfilgrastim; Pharmacokinetics

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHYLPREDNISOLONE; OXALIPLATIN; PACLITAXEL; PLACEBO; PREDNISONE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TOPOTECAN; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLERGIC REACTION; ALOPECIA; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CHEMOTEHERAPY INDUCED NEUTROPENIA; CHEMOTHERAPY INDUCED NEUTROPENIA; COLORECTAL CANCER; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; FEVER; HODGKIN DISEASE; HUMAN; INFECTION; LARGE CELL LYMPHOMA; LEUKOCYTOSIS; LUNG NON SMALL CELL CANCER; LYMPHOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL; NONHODGKIN LYMPHOMA; OVARY CANCER; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY DISTRESS SYNDROME; REVIEW; SICKLE CELL CRISIS; SINGLE DRUG DOSE; SPLEEN RUPTURE; TREATMENT OUTCOME; VOMITING;

ANTINEOPLASTIC AGENTS; GRANULOCYTE COLONY-STIMULATING FACTOR; HALF-LIFE; HUMANS; NEOPLASMS; NEUTROPENIA; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84871874902     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000345626     Document Type: Review

References (100)

1. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO: Model of chemotherapyinduced myelosuppression with parameter consistency across drugs. J Clin Oncol 2002; 20: 4713-4721.
2. Myeloid Growth Factors: National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, version 1.2010. http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp
3. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, et al: 2006 Update of recommendations for the use of white blood cell growth factors: an evidencebased clinical practice guideline. J Clin Oncol 2006; 24: 3187-3205.
4. Lyman GH, Dale DC, Crawford J: Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003; 21: 4524-4531.
5. Demetri GD, Griffin JD: Granulocyte colony-stimulating factor and its receptor. Blood 1991; 78: 2791-2808.
6. Nicola NA: Hemopoietic cell growth factors and their receptors. Annu Rev Biochem 1989; 58: 45-77.
7. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, et al: EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006; 42: 2433-2453.
8. Lyman GH, Dale DC, Wolff DA, Culakova E, Poniewierski MS, Kuderer NM, Crawford J: Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol 2010; 28: 2914-2924.
9. Morishita M, Leonard RC: Pegfilgrastim; a neutrophil mediated granulocyte colony stimulating factor-expanding uses in cancer chemotherapy. Expert Opin Biol Ther 2008; 8: 993-1001.
10. Neulasta® . In: pegfilgrastim. Thousand Oaks, Amgen Inc., 2010.
11. Kuderer NM, Dale DC, Crawford J, Lyman GH: Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007; 25: 3158-3167.
12. Lyman GH: Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action. Expert Opin Biol Ther 2005; 5: 1635-1646.
13. Molineux G: The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des 2004; 10: 1235-1244.
14. Molineux G: Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients. Anticancer Drugs 2003; 14: 259-264.
15. Yang BB, Kido A: Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet 2011; 50: 295-306.
16. Bociek RG, Armitage JO: Hematopoietic growth factors. CA Cancer J Clin 1996; 46: 165-184.
17. Souza LM, Boone TC, Gabrilove J, Lai PH, Zsebo KM, Murdock DC, Chazin VR, Bruszewski J, Lu H, Chen KK, et al: Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 1986; 232: 61-65.
18. Duhrsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D: Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988; 72: 2074-2081.
19. Welte K, Bonilla MA, Gillio AP, Boone TC, Potter GK, Gabrilove JL, Moore MA, O'Reilly RJ, Souza LM: Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates. J Exp Med 1987; 165: 941-948.
20. Begley CG, Lopez AF, Nicola NA, Warren DJ, Vadas MA, Sanderson CJ, Metcalf D: Purified colony-stimulating factors enhance the survival of human neutrophils and eosinophils in vitro: a rapid and sensitive microassay for colony-stimulating factors. Blood 1986; 68: 162-166.
21. Bronchud MH, Potter MR, Morgenstern G, Blasco MJ, Scarffe JH, Thatcher N, Crowther D, Souza LM, Alton NK, Testa NG, et al: In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients. Br J Cancer 1988; 58: 64-69.
22. Lord BI, Molineux G, Pojda Z, Souza LM, Mermod JJ, Dexter TM: Myeloid cell kinetics in mice treated with recombinant interleukin-3, granulocyte colony-stimulating factor (CSF), or granulocyte-macrophage CSF in vivo. Blood 1991; 77: 2154-2159.
23. Ulich TR, del Castillo J, Souza L: Kinetics and mechanisms of recombinant human granulocyte-colony stimulating factor-induced neutrophilia. Am J Pathol 1988; 133: 630-638.
24. Mukae H, Zamfir D, English D, Hogg JC, van Eeden SF: Polymorphonuclear leukocytes released from the bone marrow by granulocyte colony-stimulating factor: intravascular behavior. Hematol J 2000; 1: 159-171.
25. Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G: Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996; 88: 1907-1929.
26. Frampton JE, Lee CR, Faulds D: Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia. Drugs 1994; 48: 731-760.
27. Neupogen® . In: filgrastim. Thousand Oaks, Amgen, Inc., 2010.
28. Gatzemeier U, Ciuleanu T, Dediu M, Ganea-Motan E, Lubenau H, Del Giglio A: XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. J Thorac Oncol 2009; 4: 736-740.
29. Jelkmann W: Biosimilar epoetins and other 'follow-on' biologics: update on the European experiences. Am J Hematol 2010, E-pub ahead of print.
30. Kuwabara T, Kobayashi S, Sugiyama Y: Pharmacokinetics and pharmacodynamics of a recombinant human granulocyte colonystimulating factor. Drug Metabol Rev 1996; 28: 625-658.
31. Roskos L, Cheung E, Vincent M: Roskos LK, Cheung E, Vincent M, et al: Pharmacokinetics and pharmacodynamics of a recombinant human granulocyte colony-stimulating factor; in Morstyn G, Dexter M (eds): Filgrastim (r-metHuG-CSF) in Clinical Practice, ed 2. New York, Marcel Dekker, 1998, pp 51-71.
32. Haithcox S, C RR, Lee H, Lu J, Lyman GH: The impact of frequent injections for hematopoietic growth factor support on patients receiving chemotherapy: an observational study. BMC Nurs 2003; 2: 2.
33. Veronese FM, Mero A: The impact of PEGylation on biological therapies. BioDrugs 2008; 22: 315-329.
34. Jain A, Jain SK: PEGylation: an approach for drug delivery. A review. Critical reviews in therapeutic drug carrier systems 2008; 25: 403-447.
35. Jevsevar S, Kunstelj M, Porekar VG: PEGylation of therapeutic proteins. Biotechnol J 2010; 5: 113-128.
36. Caliceti P, Veronese FM: Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2003; 55: 1261-1277.
37. Harris JM, Martin NE, Modi M: Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001; 40: 539-551.
38. Galluppi GR, Rogge MC, Roskos LK, Lesko LJ, Green MD, Feigal DW Jr, Peck CC: Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference report. Clin Pharmacol Ther 2001; 69: 387-399.
39. Krzyzanski W, Wiczling P, Lowe P, Pigeolet E, Fink M, Berghout A, Balser S: Population modeling of filgrastim PK-PD in healthy adults following intravenous and subcutaneous administrations. J Clin Pharmacol 2010; 50(9 suppl):101S-112S.
40. Wang B, Ludden TM, Cheung EN, Schwab GG, Roskos LK: Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers. J Pharmacokinet Pharmacodynamics 2001; 28: 321-342.
41. Wiczling P, Lowe P, Pigeolet E, Ludicke F, Balser S, Krzyzanski W: Population pharmacokinetic modelling of filgrastim in healthy adults following intravenous and subcutaneous administrations. Clin Pharmacokinet 2009; 48: 817-826.
42. Layton JE, Hockman H, Sheridan WP, Morstyn G: Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor. Blood 1989; 74: 1303-1307.
43. Sturgill MG, Huhn RD, Drachtman RA, Ettinger AG, Ettinger LJ: Pharmacokinetics of intravenous recombinant human granulocyte colony-stimulating factor (rhG-CSF) in children receiving myelosuppressive cancer chemotherapy: clearance increases in relation to absolute neutrophil count with repeated dosing. Am J Hematol 1997; 54: 124-130.
44. Stute N, Santana VM, Rodman JH, Schell MJ, Ihle JN, Evans WE: Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. Blood 1992; 79: 2849-2854.
45. Kuwabara T, Uchimura T, Kobayashi H, Kobayashi S, Sugiyama Y: Receptor-mediated clearance of G-CSF derivative nartograstim in bone marrow of rats. Am J Physiol 1995; 269(1 Pt 1):E1-E9.
46. Terashi K, Oka M, Ohdo S, Furukubo T, Ikeda C, Fukuda M, Soda H, Higuchi S, Kohno S: Close association between clearance of recombinant human granulocyte colony-stimulating factor (G-CSF) and G-CSF receptor on neutrophils in cancer patients. Antimicrob Agents Chemother 1999; 43: 21-24.
47. Nicola NA, Metcalf D: Binding of 125I-labeled granulocyte colony-stimulating factor to normal murine hemopoietic cells. J Cell Physiol 1985; 124: 313-321.
48. Tanaka H, Tokiwa T: Influence of renal and hepatic failure on the pharmacokinetics of recombinant human granulocyte colonystimulating factor (KRN8601) in the rat. Cancer Res 1990; 50: 6615-6619.
49. Yang BB, Lum PK, Hayashi MM, Roskos LK: Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats. J Pharmaceut Sci 2004; 93: 1367-1373.
50. Emmanouel DS, Lindheimer MD, Katz AI: Role of the kidney in hormone metabolism and its implications in clinical medicine. Klin Wochenschr 1980; 58: 1005-1012.
51. Maack T, Johnson V, Kau ST, Figueiredo J, Sigulem D: Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. Kidney Intern 1979; 16: 251-270.
52. Nielsen JT: Handling of proteins in isolated and in vitro perfused proximal tubules from rabbit kidney. Dan Med Bull 1990; 37: 197-210.
53. Yang BB, Carithers E, Mayer C, Meza L: Pegfilgrastim is eliminated primarily by neutrophil-mediated clearance with minimal renal clearance. Pharmcotherapy 2003; 23: 406.
54. Fukuda M, Oka M, Ishida Y, Kinoshita H, Terashi K, Kawabata S, Kinoshita A, Soda H, Kohno S: Effects of renal function on pharmacokinetics of recombinant human granulocyte colony-stimulating factor in lung cancer patients. Antimicrob Agents Chemother 2001; 45: 1947-1951.
55. Yang BB: Integration of pharmacokinetics and pharmacodynamics into the drug development of pegfilgrastim, a pegylated protein; in Meibohm B (ed): Pharmacokinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies in Drug Development. Weinheim, Wiley-VCH Verlag, 2006, pp 373-393.
56. Yang BB, Kido A, Salfi M, Swan S, Sullivan JT: Pharmacokinetics and pharmacodynamics of pegfilgrastim in subjects with various degrees of renal function. J Clin Pharmacol 2008; 48: 1025-1031.
57. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. New Engl J Med 1991; 325: 164-170.
58. Johnston E, Crawford J, Blackwell S, Bjurstrom T, Lockbaum P, Roskos L, Yang BB, Gardner S, Miller-Messana MA, Shoemaker D, et al: Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000; 18: 2522-2528.
59. Holmes FA, Jones SE, O'Shaughnessy J, Vukelja S, George T, Savin M, Richards D, Glaspy J, Meza L, Cohen G, et al: Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 2002; 13: 903-909.
60. Sierra J, Szer J, Kassis J, Herrmann R, Lazzarino M, Thomas X, Noga SJ, Baker N, Dansey R, Bosi A: A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. BMC Cancer 2008; 8: 195.
61. Mayani H: Human preleukemia: cellular, molecular and clinical aspects. Arch Med Res 1993; 24: 317-325.
62. Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, et al: Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002; 20: 727-731.
63. Spunt SL, Irving H, Frost J, Sender L, Guo M, Yang BB, Dreiling L, Santana VM: Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients. J Clin Oncol 2010; 28: 1329-1336.
64. Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, et al: A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14: 29-35.
65. George S, Yunus F, Case D, Yang BB, Hackett J, Shogan JE, Meza LA, Neumann TA, Liang BC: Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2003; 44: 1691-1696.
66. Grigg A, Solal-Celigny P, Hoskin P, Taylor K, McMillan A, Forstpointner R, Bacon P, Renwick J, Hiddemann W: Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2003; 44: 1503-1508.
67. Hecht JR, Pillai M, Gollard R, Heim W, Swan F, Patel R, Dreiling L, Mo M, Malik I: A randomized, placebo-controlled phase II study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Clin Colorectal Cancer 2010; 9: 95-101.
68. Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, Neumann TA, Schwartzberg LS: First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005; 23: 1178-1184.
69. Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J, Frankel S, Flinn I, Lovelace W, Hackett J, et al: Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003; 21: 514-519.
70. Mey UJ, Maier A, Schmidt-Wolf IG, Ziske C, Forstbauer H, Banat GA, Reber M, Strehl JW, Gorschlueter M: Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. Support Care Cancer 2007; 15: 877-884.
71. Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, Lyman G: Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2007; 23: 2283-2295.
72. Schippinger W, Holub R, Dandachi N, Bauernhofer T, Samonigg H: Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim. Oncology 2006; 70: 290-293.
73. von Minckwitz G, Kummel S, du Bois A, Eiermann W, Eidtmann H, Gerber B, Hilfrich J, Huober J, Costa SD, Jackisch C, et al: Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/ cyclophosphamide) chemotherapy for breast cancer. Results from the GeparTrio study. Ann Oncol 2008; 19: 292-298.
74. Kubista E, Glaspy J, Holmes FA, Green MD, Hackett J, Neumann T: Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. Clin Breast Cancer 2003; 3: 391-398.
75. Gregory S, Schwartzberg L, Mo M, Sierra J, Vogel C: Evaluation of reported bone pain in cancer patients receiving chemotherapy in pegfilgrastim clinical trials: a retrospective analysis. Commun Oncol 2010; 7: 297-306.
76. Wolff AC, Jones RJ, Davidson NE, Jeter SC, Stearns V: Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support. J Clin Oncol 2006; 24: 2392-2394; author reply 2394-2395.
77. Yang BB, Kido A, Shibata A: Serum pegfilgrastim concentrations during recovery of absolute neutrophil count in patients with cancer receiving pegfilgrastim after chemotherapy. Pharmacotherapy 2007; 27: 1387-1393.
78. Kaplinsky C, Trakhtenbrot L, Hardan I, Reichart M, Daniely M, Toren A, Amariglio N, Rechavi G, Izraeli S: Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSF. Bone Marrow Transplant 2003; 32: 31-34.
79. Nagler A, Korenstein-Ilan A, Amiel A, Avivi L: Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. Exp Hematol 2004; 32: 122-130.
80. Crawford J, Dale DC, Kuderer NM, Culakova E, Poniewierski MS, Wolff D, Lyman GH: Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw 2008; 6: 109-118.
81. Ozer H, Mirtsching B, Rader M, Luedke S, Noga SJ, Ding B, Dreiling L: Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use. Oncologist 2007; 12: 484-494.
82. Braess J, Spiekermann K, Staib P, Gruneisen A, Wormann B, Ludwig WD, Serve H, Reichle A, Peceny R, Oruzio D, et al: Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. Blood 2009; 113: 3903-3910.
83. Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Moy B, et al: Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol 2005; 23: 8340-8347.
84. Dalla Chiesa M, Tomasello G, Buti S, Kraft Rovere R, Brighenti M, Lazzarelli S, Donati G, Passalacqua R: Sequential chemotherapy with dose-dense docetaxcel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial. Cancer Chemother Pharmacol 2010, Epub ahead of print.
85. Invernizzi R, Grasso D, Travaglino E, Benatti C, Collova E, Manzoni M, Livraghi L, Danova M, Riccardi A: Biological effects of pegfilgrastim on circulating neutrophils in breast cancer patients undergoing dose-dense chemotherapy. Oncology 2008; 75: 237-244.
86. Jones RL, Walsh G, Ashley S, Chua S, Agarwal R, O'Brien M, Johnston S, Smith IE: A randomised pilot phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer. Br J Cancer 2009; 100: 305-310.
87. Manzoni M, Delfanti S, Rovati B, Grasso D, Mariucci S: Chemotherapy-induced anemia in breast cancer patients treated with pegfilgrastim-supported dose-dense regimens. Clin Exp Med 2010; 10: 135-138.
88. Miller AA, Wang XF, Gu L, Hoffman P, Khatri J, Dunphy F, Edelman MJ, Bolger M, Vokes EE, Green MR: Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303). J Thorac Oncol 2008; 3: 1159-1165.
89. Aapro M, Schwenkglenks M, Lyman GH, Lopez Pousa A, Lawrinson S, Skacel T, Bacon P, von Minckwitz G: Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy. Crit Rev Oncol Hematol 2010; 74: 203-210.
90. Balducci L, Al-Halawani H, Charu V, Tam J, Shahin S, Dreiling L, Ershler WB: Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 2007; 12: 1416-1424.
91. Romieu G, Clemens M, Mahlberg R, Fargeot P, Constenla M, Schutte M, Easton V, Skacel T, Bacon P, Brugger W: Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial. Crit Rev Oncol Hematol 2007; 64: 64-72.
92. Meropol NJ, Miller LL, Korn EL, Braitman LE, MacDermott ML, Schuchter LM: Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. J Natl Cancer Inst 1992; 84: 1201-1203.
93. Burris HA, Belani CP, Kaufman PA, Gordon AN, Schwartzberg LS, Paroly WS, Shahin S, Dreiling L, Saven A: Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non-small-cell lung cancer, ovarian cancer, and non-Hodgkin's lymphoma: results of four multicenter, double-blind, randomized phase II studies. J Oncol Pract 2010; 6: 133-140.
94. Skarlos DV, Timotheadou E, Galani E, Samantas E, Grimani I, Lianos E, Aravantinos G, Xanthakis I, Pentheroudakis G, Pectasides D, et al: Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group. Oncology 2009; 77: 107-112.
95. Eldar-Lissai A, Cosler LE, Culakova E, Lyman GH: Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health 2008; 11: 172-179.
96. Siena S, Piccart MJ, Holmes FA, Glaspy J, Hackett J, Renwick JJ: A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily filgrastim in patients with stage II-IV breast cancer. Oncol Rep 2003; 10: 715-724.
97. von Minckwitz G, Schwenkglenks M, Skacel T, Lyman GH, Pousa AL, Bacon P, Easton V, Aapro MS: Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis. Eur J Cancer 2009; 45: 608-617.
98. Weycker D, Malin J, Kim J, Barron R, Edelsberg J, Kartashov A, Oster G: Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. Clin Ther 2009; 31: 1069-1081.
99. Lyman GH, Kuderer NM: Filgrastim in patients with neutropenia: potential effects on quality of life. Drugs 2002; 62(suppl 1):65-78.
100. Engert A, Bredenfeld H, Dohner H, Ho AD, Schmitz N, Berger D, Bacon P, Skacel T, Easton V, Diehl V: Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study. Haematologica 2006; 91: 546-549.